Non-opioid pain treatments

Source date: October 8, 2026; enrollment-completion event October 2. Saol reports completed enrollment for BEACON (NCT07226258), randomized masked phase 3 SL1002 versus placebo for knee-OA pain at over twenty U.S. sites. SL1002 is a targeted perineural chemoneurolytic injection. The primary endpoint is week-12 change in walking-pain intensity; this is symptom treatment, not cartilage regeneration.

Limits/safety: No new effect estimate, participant disposition or harms table. The August 25 registry still says recruiting with 150 estimated participants; it is stale relative to the sponsor milestone and does not establish the final analyzed sample. Chronic pain/function, durability and nerve-related harms need comparative results.

U.S./next: Investigational. Sponsor forecasts topline Q2 2027 and plans another phase 3 knee study. A granted End-of-Phase-2 FDA meeting concerns a separate spasticity program; meeting permission is neither agreement on final design nor approval.

October 8 original sponsor release; registry.

Registry updated October 9, 2026. NCT06696443, the suzetrigine painful-diabetic-peripheral-neuropathy extension, is now active, not recruiting, with 455 actual participants. It began December 18, 2024 and has estimated primary/final completion January 25, 2027. The single-arm open-label design primarily assesses adverse and serious adverse events through week 54; symptoms and health status are secondary.

Limits/safety/U.S.: No results are posted. Enrollment closure is not study completion, demonstrated safety or a positive efficacy readout. This extension cannot isolate a treatment effect without a comparator. Suzetrigine’s existing acute-pain approval does not establish a diabetic-neuropathy indication.

Next: Completion is estimated, not a promised result date. Follow the separate randomized pivotal efficacy studies and eventual label decisions.

Primary registry.

First posted October 8, 2026; registry-reported actual start October 7. NCT07864896 plans 148 participants in a randomized, masked phase 3 suzetrigine-versus-placebo trial at Hospital for Special Surgery. Primary total knee arthroplasty patients receive study treatment for fourteen days. The primary endpoint is cumulative opioid consumption over forty-eight hours; secondary pain and opioid-use assessments continue through later postoperative visits.

Limits/safety/U.S.: No results or harms rates. Less rescue opioid use would need interpretation alongside pain control, ambulation and adverse effects. One primary time-frame line mistakenly says THA despite a TKA protocol; retain this registry inconsistency. Research extends evidence for an already acute-pain-approved drug and is not a new chronic-pain approval.

Next: Recruiting; January 2029 primary and January 2030 final completion are month-precision estimates, not publication promises.

Primary registry.

Remaining gaps: All saved named NCT records refreshed and all pages of official overlap discovery screened (49 returned records). Search starts September 5/6 from the last full successful check, not October 6 alone. Incidental matches excluded; literature, international registries, all regulatory files and complete podcast/audio appraisal remain incomplete.; Broad trial discovery also located NIH experimental-pain HNK and another rotator-cuff suzetrigine study, not promoted as patient efficacy. Full VX-993 and other chronic-pain safety, surgery abstracts and international records remain incompletely appraised.

Informal-source coverage: Read original r/anesthesiology Journavx thread. Anonymous clinician/patient accounts conflict on relief and opioid substitution; mixed regimens, uncontrolled samples and unverified insurance claims are not trial outcomes or reliable coverage estimates. No distinctive formal-development rumor selected; full Radiolab/podcast audio not appraised.

Full coverage record.

Baseline source date: Published online August 8, 2026, not a new October trial; October is the journal issue. Evidence: Open-label single-arm phase 4 NCT06887959.

Forty-seven adults undergoing arthroscopic/laparoscopic surgery received suzetrigine within a multimodal analgesic regimen for up to 14 days. Good/very-good/excellent end-of-treatment ratings occurred in 90.9%; 76.1% did not require opioid rescue. One aspiration serious adverse event was considered unrelated.

Limits: Sponsor-supported, small and uncontrolled. Acetaminophen, anti-inflammatory medicines and procedure-specific adjuncts contribute to analgesia; no causal opioid-sparing comparison or chronic-pain efficacy is established.

U.S./next milestone: Existing adult acute-pain approval is separate from investigational chronic uses. Controlled trials remain needed; no readout inferred.

Full primary paper; registry.

Source date: October 2, 2026 first registry posting. Evidence: NCT07856654, planned phase 4 randomized masked study in 48 adults after urogynecologic surgery.

Suzetrigine or matching placebo is added to the same multimodal analgesic background. Primary outcome: seven-day change in pain score. Secondary measures include opioid consumption, recovery satisfaction and tolerability.

Limits/safety/U.S.: Not yet recruiting; no benefit or safety result. Existing acute-pain authorization is not evidence this specific regimen improves recovery.

Next: November 2026 start, December 2027 primary completion and May 2028 final completion are registry estimates, not promised readouts.

Primary registry.

Source/event date: 2026-07-23. Evidence: Peer-reviewed randomized pilot-trial abstract; historical context.

PEPTIDE randomized 44 adults aged 18–60 with chronic inflammatory-like low back pain, Modic type 1 MRI changes and inadequate NSAID response to two daily 90-mg pamidronate infusions or placebo. At three months, the primary pain-score difference was −6.4 mm on a 100-mm scale (95% CI −22.0 to 9.3), without statistically significant benefit. A six-week difference also crossed zero. Adverse events occurred in 54.6% versus 27.3%, mainly influenza-like symptoms. This small trial does not establish durable analgesia, fracture healing or cartilage repair. The paper appeared online July 23 and in a September issue; this is recovered baseline context, not October news. Primary abstract.

Next milestone: No confirmatory-trial milestone or date verified.

Primary abstract.

Source date: 2026-09-25. Event date: 2026-09-25. Evidence: Peer-reviewed cluster randomized trial.

An integrated nonpharmacologic perioperative-care strategy reduced opioid exposure but did not improve its coprimary patient-reported outcomes. NOHARM included 68,141 surgical procedures across 22 practices at six U.S. centers. Adjusted PROMIS differences were .09 for pain interference (95% CI −.18 to .36; p=.51) and .15 for physical function (−.11 to .41; p=.27). Secondary opioid exposure rate ratio was .90 (.82–.99; p=.03). Trial: NCT04570371.

Limitations: Stepped-wedge cluster design; procedure count is not unique-patient count. Prescription/administration records are not complete consumption data. Approximately 70% patient-reported response and a predominantly White single-system population limit generalizability.

Safety: No significant adverse-event or utilization change reported. Reduced opioid exposure is not demonstrated prevention of addiction or mortality.

U.S. status: A care-delivery intervention, not a new drug approval.

Next milestone: Replication and longer-term implementation outcomes; timing unknown.

NOHARM randomized clinical trial, JAMA Network Open.

Source date: 2026-09-21. Event date: 2026-09-21. Evidence: Sponsor topline announcement.

Novo reported improved pain ratings in type 2 diabetes with painful peripheral neuropathy, and plans Phase 3 neuropathy trials across its portfolio during 2027. NCT06797869 randomized quadruple-masked trial: registry enrollment 142; slide analysis n=141. At the registered 32-week endpoint, CagriSema 2.4/2.4 mg reduced PI-NRS by 2.4 points versus 1.3 with placebo, from baseline 6.4; efficacy estimand, on top of standard care. More than 53% of treated participants achieved ≥30% pain reduction; comparator response not supplied.

Limitations: Sponsor slide only, no CI or exact p-value; pain relief is not nerve regeneration or prevention of diabetic complications. Analysis and enrollment denominators differ.

Safety: Only qualitative statement that safety/tolerability resembled prior CagriSema trials; no new quantitative table.

U.S. status: Investigational for this use; no new U.S. approval.

Next milestone: Phase 3 trials in painful diabetic neuropathy during 2027, sponsor plan with no specific start date.

Novo Diabetes CMD, slide 10; NCT06797869 registry.

Related findings:

• CBL-514 reports reduced Dercum lipoma pain in Phase 2.

Source date: 2026-09-17. Evidence: Sponsor protocol-development announcement.

MIRA submitted a phase 2a chemotherapy-induced neuropathy protocol for ethics review; site initiation is targeted for Q1 2027, not confirmed underway. After FDA feedback, the planned randomized double-blind crossover study compares oral Ketamir-2 300 mg, 600 mg and placebo across three seven-day periods with washouts in adults with persistent moderate-to-severe chemotherapy-induced peripheral neuropathy. Enrollment size and a matched registry identifier were not established in the release.

Limitations: Healthy-volunteer phase 1 tolerability does not establish pain relief, function or chronic safety in patients. This oral NMDA-modulator program is distinct from approved suzetrigine and from psychedelic depression trials.

Safety: Sponsor reports no serious events or dose-limiting toxicity in phase 1; phase 2 comparative safety and CNS effects remain unmeasured.

U.S. status: Investigational; FDA protocol review and an active IND are not marketing approval.

Next milestone: Q1 2027 site initiation is conditional on IRB review and activation. An October 5–6 presentation concerns phase 1/development, not phase 2 efficacy.

MIRA, September 17.

Suzetrigine / VX-548 / Journavx is a selective peripheral NaV1.8 sodium-channel inhibitor. The FDA approved it on January 30, 2025 for moderate-to-severe acute pain in adults. Two randomized 48-hour trials after abdominoplasty (NCT05558410) and bunionectomy (NCT05553366) established superiority over placebo on time-weighted pain reduction. A separate open-label trial, NCT05661734, contributed safety data. FDA trial review and approval summary.

The active comparator was hydrocodone/acetaminophen, and rescue ibuprofen was allowed. The studies did not establish superiority to that opioid combination: its average pain-relief score was slightly lower than suzetrigine after abdominoplasty and higher after bunionectomy. Approval therefore should not be restated as proof of superior opioid replacement across surgeries. Common adverse reactions included itching, muscle spasms, creatine-phosphokinase elevation, and rash. Longer treatment and other populations require separate evidence. FDA efficacy and safety tables.

For painful diabetic peripheral neuropathy (DPN), the program includes phase 3 studies NCT06628908 and NCT07231419, plus an open-label long-term study, NCT06696443. Vertex's August 2026 update expects enrollment in both pivotal trials to finish by year-end 2026. That is an enrollment milestone, not a promised results date or a chronic-pain approval. Trial 1; trial 2; long-term study; current sponsor timeline.

Important counterexample: the December 2024 painful lumbosacral radiculopathy phase 2 study reported mean pain reductions of 2.02 points with suzetrigine versus 1.98 with placebo at week 12. Its primary analysis was change within the treated group, which was statistically significant; it was not designed or powered to establish a between-group difference. This does not demonstrate efficacy beyond placebo in radiculopathy, despite the company's “met primary endpoint” description. Sponsor's full phase 2 result.

Vertex's next NaV1.8 inhibitor, VX-993, remains investigational. The company decided not to advance it as acute-pain monotherapy because its phase 2 efficacy did not suggest superiority to suzetrigine. This was a development decision about that use, not discontinuation of the molecule: a phase 2 DPN trial continues, with enrollment completion also projected by the end of 2026. Watch whether any incremental efficacy justifies the new program and whether tolerability remains acceptable over chronic exposure. Vertex annual filing; August 2026 pipeline update.

Tonmya / TNX-102 SL is sublingual cyclobenzaprine, a centrally acting drug with a long-established active ingredient, newly approved for adult fibromyalgia on August 15, 2025. This is a new formulation and indication, not a newly discovered molecular class. Approval announcement; current prescribing information.

The peer-reviewed RESILIENT trial, NCT05273749, analyzed 456 participants over 14 weeks. Average pain decreased by 1.8 points versus 1.2 with placebo, with statistically significant benefits in sleep, fatigue, and other prespecified outcomes. An earlier trial, RALLY, did not significantly separate from placebo; both successes and that failure belong in the record. The studies do not establish superiority to duloxetine, pregabalin, or existing oral cyclobenzaprine. RESILIENT publication; sponsor's three-trial disclosure.

Local mouth reactions are frequent: pooled labeling reports oral numbness in 23% versus 0.7% and somnolence in 6% versus 2%. The label also contains cardiac contraindications and serotonin-syndrome warnings relevant to combinations with some antidepressants. Longer-term effectiveness and comparative tolerability deserve monitoring. Prescribing information.